Tracer library / [177Lu]Lu-satoreotide

Structure of satoreotide (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 121488181

[177Lu]Lu-satoreotide

Also written as [Lu-177]Lu-satoreotide; [Lu-177]Lu-Satoreotide; Lu-177-Satoreotide

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: satoreotide tetraxetan (DOTA-conjugated somatostatin receptor antagonist peptide)
Target / mechanism: Somatostatin receptor 2 (SST2) antagonist PMID 36145306
Clinical application: Somatostatin receptor-positive neuroendocrine tumors PMID 40796453
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	>97%	>90%	satoreotide tetraxetan Octreopharm/Ipsen, Berlin, Germany	36145306 2022 Pharmaceuticals (Basel)

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Octreopharm/Ipsen
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-satoreotide, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36145306: 'The peptide conjugate satoreotide tetraxetan was supplied by Octreopharm/Ipsen (Berlin, Germany)'. Stage set/updated at stage 39 from PMID 40796453: 'we review both preclinical and clinical data evaluating the efficacy and safety of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in the treatment of neuroendocrine tumors'.